Multiple sclerosis, an autoimmune disorder causing the destruction of the impulse carrying myelin sheath of neurons, can be a debilitating and disabling disease. Symptomatic treatment has provided patients with relief through the use of antispasmodics, anticholinergics, and antidepressants, just to name a few, as well as disease treatment by decreasing progression of the illness by treating acute episodes through the use of corticosteroids, interferons, plasmapheresis, and other immunomodulators like glatiramer, mitoxantrone, and natalizumab. With medical advancements and the development of new treatments such as laquinimod, fampridine-SR, and several others, the future looks promising for those living with this illness.
TruyenLvan WuesbergheJHTMBarkofF.
Accumulation of hypointense lesions (“blackholes”) on T1 spinecho MRI correlates with disease progression in multiple sclerosis.
Neurology.47:1469–1476.
7.
LassmanHSuchanekGOzawaK.
Histopathology and the blood cerebrospinal fluid barrier in multiple sclerosis.
Ann Neurol. 36(suppl):S42–S46.
8.
WeinshenkerBG. Natural history of multiple sclerosis. Ann Neurol. 1994;36(suppl):S6–S11.
9.
ConfavreuxCVukusicSMoreauT. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430–1438.
10.
CalabresiM. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004;70(10):1935–1944.
11.
AnderssonPGoodkinD. Current pharmacological treatments of multiple sclerosis. West J Med. 1996;165(5):313–317.
12.
Prednisone Monograph. Micromedex. www.thomsonhc.com. Accessed September 8, 2009.
LublinFDWhitakerJNEidelmanBH. Management of patients receiving interferon beta-1b for multiple sclerosis. Report of a consensus conference. Neurology. 1996;46(1):12–18.
18.
The IFNB Multiple Sclerosis Study Group.. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology. 1993;43(4):655–661.
19.
KapposLFreedmanMSPolmanCH. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–1249.
20.
FrohmanEPhillipsTKokelK. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurology. 2002;8(4):227–236.
21.
TselisAKhanOLisakR. Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2007;3(2):259–267.
22.
Glatiramer Acetate Monograph. Micromedex. www.thomsonhc.com. Accessed September 8, 2009.
23.
Mitoxantrone Monograph. Micromedex. www.thomsonhc.com. Accessed September 8, 2009.
24.
HartungPKonigNKwiecinskiH. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised multicentre trial. Lancet. 2002;360(9350):2018–2025.
25.
25. Novantrone [package insert]. Melville, NY: OSI Pharmaceuticals Inc; 2008.
26.
How Tysabri Works: Mechanism of Action. Tysabri website. www.Tysabri.com. Accessed September 8, 2009.
Long term efficacy and safety of FTY720 in patients with relapsing-remitting multiple sclerosis. 2008. http://clinicaltrials.gov. Accessed November 28, 2008.
33.
Assessment Study of steroid effect in relapsing multiple sclerosis subjects treated with glatiramer acetate. 2008. http://clinicaltrials.gov. Accessed November 28, 2008.
34.
BrightSChumbleyGHaleG. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62(4):873–882.
35.
Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data, Selected for Scientific Highlights Program at the American Academy, of Neurology Meeting. Bio-Medicine. 2008. http://www.bio-medicine.org. Accessed December 1, 2008.
36.
The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Eng J Med. 2008;359(17):1786–1801.
37.
Therapeutics & Diagnostics for Autoimmune Diseases and Allergies. Apitope International NV. (2008). http://www.apitope.com. Accessed September 7, 2009.
38.
CatzIFerencziZWarrenKG. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13(8):887–895.
39.
GironiMSolaroCZaffaroniM. A pilot trial of low-dose Naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008;14(8):1076–1083.
40.
AgrawalY. Low dose Naltrexone therapy in multiple sclerosis. Med Hypotheses. 2005;64(4):721–724.
KapposLAntelJComiG. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Eng J Med. 2006;355(11):1124–1140.
47.
PolmanCBarkhofFSandberg-WollheimM. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64(6):987–991.
48.
ComiGPulizziARovarisM. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;21:371(9630):2085–2092.
New data illustrate novel mechanism of action of laquinimod, an oral compound for the treatment of multiple sclerosis. 2009April. Active Biotech. <http://hugin.info/1002/R/1309008/302086.pdf>. Accessed September 8, 2009.
